Myosana Therapeutics
myosanatherapeutics.com
Rare Disease Therapeutics
Biotechnology
Cell & Gene Therapy
As featured in
Claim pageClaim
Follow
Overview
Connections
News
Salaries
Products
People
Growth
Offices
Financials
Funding and backers
Total raised
$12.4M
3 rounds on record
Latest round
$5M
Seed · Jan 2023 · 3 yr ago
Team
11-50
employees, estimated range
The money's age
Long since its last round
45 months since the last round · not hiring
Momentum
0/100
no fresh signals
Last sign of life
this month
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Funding rounds
| Round | Date | Amount | Investors | Source |
|---|---|---|---|---|
| Seed | Jan 2023 | $5M | — | businesswire.com |
| Venture round | Nov 2022 | $6.4M | — | SEC Form D |
| Seed | Apr 2020 | $1M | — | myosanatherapeutics.com |
Registers and programsofficial lists and records that name the company
| Legal entity | Myosana Therapeutics, Inc. | SEC Form D |
Founders and leadersfrom filings, registers and the company's site
Stanley FroehnerExecutive Officer, DirectorSEC Form D
Nicholas WhiteheadExecutive Officer, DirectorSEC Form D
Investors in similar startupsfunds that back the companies most like this one
Similar startupsby what they do, their industry and backers
Code Biotherapeutics is an emerging next-generation gene therapy company pioneering the development of targeted non-viral gene therapies to…
ViaNautis is transforming cell and gene therapy with polyNaut®, a versatile, non-viral, targeted polymer-based nanovesicles delivery system…
Affinia Therapeutics is expanding what's possible in adeno-associated virus (AAV) gene therapy today and bringing transformative medicines…
Borea therapeuticsBorea Therapeutics: Next-generation viral vectors for targeted gene therapy.
Tessera Therapeutics is a biotechnology company pioneering Gene Writing technology to develop genetic medicines. It is developing in vivo…
GeneVentiv Therapeutics — advancing gene therapy approaches.
News
Parent Project Muscular Dystrophy Invests $500,000 in Myosana Therapeutics to Advance Non-Viral Gene Therapy Platform
/PRNewswire/ -- Parent Project Muscular Dystrophy (PPMD), a nonprofit organization leading the fight to end Duchenne muscular dystrophy (Duchenne), today...
Read more
Report
Myosana Therapeutics Raises $5 Million in Seed Funding
SEATTLE-(BUSINESS WIRE)-Myosana Therapeutics, Inc., pioneer of a muscle-specific non-viral gene therapy platform for neuromuscular and cardiac diseases, today announced the completion of a seed funding round totaling over $5 million led by investor John B
Read more
Report
Muscular Dystrophy Association's Venture Philanthropy Program Announces Investment in Non-viral Gene Therapy
New York, NY - January 25, 2023, The Muscular Dystrophy Association (MDA) announces a $650,000 investment in Myosana Therapeutics via its MDA Venture Philanthropy (MVP) program. Myosana is a start-up company co-founded in 2018 from the University of Washi
Read more
Report
PPMD Invests $500,000 in Myosana Therapeutics to Advance Non-Viral Gene Therapy Platform
Parent Project Muscular Dystrophy is excited to announce a $500,000 programmatic investment in Myosana Therapeutics, Inc. (Myosana) to support the company's continuing development and translation of a non-viral gene therapy delivery platform aiming to slo
Read more
Report
Parent Project Muscular Dystrophy Invests $350,480 in Myosana Therapeutics to Support Non-Viral Gene Therapy Development
Duchenne is the most common fatal genetic disorder diagnosed in childhood, affecting approximately one in 5,000 live male births. Duchenne is caused by a change in the DMD gene that codes for the dystrophin protein. Gene therapy holds the promise of provi
Read more
Report
Myosana Therapeutics, Inc. Raises Up To $1M from CureDuchenne Ventures
NEWPORT BEACH, Calif. & SEATTLE-(BUSINESS WIRE)-Myosana Therapeutics, Inc., a new biotech company developing novel platform technology for non-viral gene delivery, raised up to $1M in seed financing from CureDuchenne Ventures. Myosana will use this initia
Read more
Report
People
Stanley Froehner
Executive Officer, Director
Nicholas Whitehead
Executive Officer, Director
Matthew Lumley
Director
Debra Miller
Director
Names and roles come from public filings, company registers and the company's own site. Is this you? Correct or remove · How we handle this data
Offices
Where the company hires and what each office is for
Cities
1
Hiring now
0
Countries
1
Seattle
United States
HQ
10-50 est. staff